Market Overview

Alexion Pharmaceuticals' Rebound To Continue -Vetr Crowd

Alexion Pharmaceuticals' Rebound To Continue -Vetr Crowd
Related ALXN
Earnings Scheduled For October 26, 2017
Is A Beat In Store For Alexion This Earnings Season?
The Next Billion Dollar Blockbuster: Why Value Investors Should Look At Omeros Corporation (Part 1) (Seeking Alpha)

Shares of Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) have lost 32.5 percent of their value since the beginning of the year. However, over the third quarter, the stock has recuperated more than 12.6 percent, and the Vetr crowd seems to believe the rebound will continue. This is evidenced by its average price target of $146.84, which implies an upside potential of almost 13.15 percent.

Related Link: Here's How Crowdsourced Ratings Can Beat The Market

Seeking to better reflect this upside potential, the Vetr community decided to upgrade its rating on shares of Alexion on Friday, from four stars (Buy) to 4.5 stars (Strong Buy) — out of a possible five-star rating.

Finally, it should be noted that, in accordance with the new rating, 87 percent of the crowd’s ratings are bullish.

Full ratings data available on Benzinga Pro.

Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!

Disclosure: Javier Hasse holds no interest in any of the securities or entities mentioned above.

Latest Ratings for ALXN

Oct 2017Stifel NicolausMaintainsBuy
Oct 2017PiperJaffrayAssumesOverweightOverweight
Sep 2017RBC CapitalInitiates Coverage OnOutperform

View More Analyst Ratings for ALXN
View the Latest Analyst Ratings

Posted-In: VetrBiotech Upgrades Health Care Price Target Crowdsourcing Analyst Ratings General


Related Articles (ALXN)

View Comments and Join the Discussion!

Partner Center